Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well cediranib maleate works in treating patients with
recurrent or newly diagnosed metastatic head and neck cancer. Cediranib maleate may stop the
growth of head and neck cancer by blocking some of the enzymes needed for cell growth and by
blocking blood flow to the tumor.